Combinations of conventional therapies with novel therapeutic agents have been constantly explored in the field of cancer drug development. This collection of 'Novel Combinations' includes a selection of recent papers published in Molecular Cancer Therapeutics (MCT) that demonstrate the enhanced efficacy of innovative combinations on preclinical cancer models. MCT welcomes submissions of original research articles in novel combinations.
- Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome
Raynal NJM…JPJ Issa. Molecular Cancer Therapeutics February 2017. - Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy
Tyler PM…Dougan SK. Molecular Cancer Therapeutics March 2017. - Combining Chk1/2 Inhibition with Cetuximab and Radiation Enhances In Vitro and In Vivo Cytotoxicity in Head and Neck Squamous Cell Carcinoma
Zeng L…Yang ES. Molecular Cancer Therapeutics April 2017. - Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Kuo HP…Chang BY. Molecular Cancer Therapeutics July 2017. - Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors
Lam LT…Uziel T. Molecular Cancer Therapeutics August 2017.
Molecular Cancer Therapeutics Editorial Office
American Association for Cancer Research | Publications Division
615 Chestnut Street | 17th Floor | Philadelphia, PA 19106-4404
Phone: (215) 440-9300 | Fax: (267) 765-1090 | E-mail: mct@aacr.org